Centessa IPO Presentation Deck
Palladio Biosciences
Developing lixivaptan, a Phase 3 stage vasopressin V2 receptor antagonist, as a potential
best-in-class therapy for autosomal dominant polycystic kidney disease (ADPKD)
Mission
Develop a differentiated therapeutic for
ADPKD that avoids liver safety issues
requiring a REMS distribution program
and with efficacy comparable to that of
tolvaptan
De-risking data
36 clinical studies and 1,600+ subjects
dosed with lixivaptan in prior clinical
program
No evidence of liver toxicity during 14
months of dosing with lixivaptan in a
patient with drug-induced liver toxicity
while on tolvaptan
PD effect of lixivaptan confirmed with
dose-related suppression of urine
osmolality in clinical pharmacology study
of 31 ADPKD subjects
PALLADIO
BIOSCIENCES
Market opportunity
Prevalence of 140,000 patients currently
diagnosed with ADPKD in US
US sales of JYNARQUE (tolvaptan) of $620
million in second full-year (2020) after
approval, reflecting ~5,000 patients on
therapy, despite black box warning
and REMS program for liver toxicity
CENTESSA 11View entire presentation